Leah Hunter Commissioner for External Affairs (OEA) within the Office of the Commissioner at the U.S. Food and Drug Administration | Official Website
Leah Hunter Commissioner for External Affairs (OEA) within the Office of the Commissioner at the U.S. Food and Drug Administration | Official Website
This is a 100% increase over the number of companies cited in the previous year.
Of the 22 citations issued, the most common citation was 'Procedures for corrective and preventive action have not been adequately established'.
Most of the companies cited were involved in the Devices sector.
Of the companies cited, one should take voluntary action to correct its managing operations (50%). Additionally, one company had to take regulatory and/or administrative actions (50%).
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Exactech, Inc. | Devices | 09/26/2023 | Report of Death or Serious Injury |
Exactech, Inc. | Devices | 09/26/2023 | Lack of or inadequate procedures |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Lack of System for Determining MDR Events |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Management representative |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Management review - Lack of or inadequate procedures |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Quality audits - Lack of or inadequate procedures |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Personnel |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Design validation - Risk analysis |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Design validation - software validation documentation |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Documentation of software validation |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Lack of or inadequate procedures |
LifeSouth Community Blood Centers, Inc. | Biologics | 11/09/2023 | Documentation |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Lack of System for Determining MDR Events |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Management representative |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Management review - Lack of or inadequate procedures |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Quality audits - Lack of or inadequate procedures |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Personnel |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Design validation - Risk analysis |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Design validation - software validation documentation |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Documentation of software validation |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Lack of or inadequate procedures |
LifeSouth Community Blood Centers, Inc. | Devices | 11/09/2023 | Documentation |